Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Energy Fuels Aktie: Achtung, Aufholpotenzial! (Aktiencheck) +++ ENERGY FUELS Aktie -3,11%

GALMED Aktie

>GALMED Performance
1 Woche: 0%
1 Monat: 0%
3 Monate: 0%
6 Monate: 0%
1 Jahr: -13,0%
laufendes Jahr: 0%
>GALMED Aktie
Name:  GALMED PHARMACEUT.IS 1,80
Land:  Israel
Sektor:  Gesundheit
ISIN/ Wkn:  IL0011313900 / A1XFUX
Symbol/ Ticker:  GPH (Frankfurt) / GLMD (NASDAQ)
Kürzel:  FRA:GPH, ETR:GPH, GPH:GR, NASDAQ:GLMD
Index:  -
Webseite:  https://galmedpharma.com/
Marktkapitalisierung:  3.11 Mio. EUR
Umsatz:  -
EBITDA:  -5.24 Mio. EUR
Gewinn je Aktie:  57.845 EUR
Schulden:  -
Liquide Mittel:  13.63 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  0.04 / -
KUV/ KBV/ PEG:  - / 0.26 / -
Gewinnm./ Eigenkapitalr.:  - / -49.58%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  GALMED
Letzte Datenerhebung:  05.07.25
>GALMED Eigentümer
Aktien: 2.26 Mio. St.
f.h. Aktien: 2.02 Mio. St.
Insider Eigner: 2.9%
Instit. Eigner: 2.55%
>GALMED Peer Group

 
27.05.25 - 14:01
 Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH (PR Newswire)
 
Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart......
22.05.25 - 14:12
 Galmed GAAP EPS of -$0.62 beats by $0.27 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.25 - 13:33
 Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer′s Regorafenib Effect in GI Cancer Models (PR Newswire)
 
Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models. The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.......
28.04.25 - 14:03
 Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation (PR Newswire)
 
The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). The new formulation is expected to offer alternatives to both approved......
17.04.25 - 14:33
 Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers (PR Newswire)
 
Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. Aramchol, a first-in-class SCD1 inhibitor, will be studied in......
15.04.25 - 14:33
 Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor (PR Newswire)
 
Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug. The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of......
10.04.25 - 14:03
 Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor (PR Newswire)
 
– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development – Aramchol Meglumine, a New Chemical Entity (NCE) protected by patents until 2035, is being developed both as a......
02.04.25 - 22:15
 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 (PR Newswire)
 
TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report......
20.03.25 - 14:00
 Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol′s Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy (PR Newswire)
 
TEL AVIV, Israel, March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related......
21.10.24 - 22:45
 Galmed Pharmaceuticals files for offering of common stock (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
19.09.24 - 20:04
 Galmed surges on plans to expand into cancer and heart disease drug development (Reuters EN)
 
Galmed surges on plans to expand into cancer and heart disease drug development...
17.09.24 - 14:18
 Pre-market Movers: GLMD, WHLR, NCPL, ALLR, RLMD. (AFX)
 
SANTA CLARA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.40 A.M. ET).In the Green Galmed Pharmaceuticals Ltd. (GLMD) is up over 49% a......
30.08.24 - 23:18
 Galmed Pharmaceuticals files to sell 416,667 of ordinary shares for holders (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.08.24 - 08:04
 XFRA : GPH: Aussetzung/Suspension (XETRA)
 
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL GALMED PHARMACEUT.IS 1,80 GPH IL0011313900 BAW/UFN...
30.08.24 - 07:37
 XFRA : INSTRUMENT_SUSPENSION - IL0011313900 (XETRA)
 
Instrument ID [5369] (GPH - IL0011313900) suspended...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!